Canine Lymphoma: Rapid Workup, Thoughtful Decisions
Lymphoma is common, often initially painless, and usually demands a diagnosis-and-plan conversation faster than owners expect.
Lymphoma planning path
Topic
| Topic | What it means | Why it matters | Owner takeaway |
|---|---|---|---|
| Painless enlarged lymph nodes | Often the first clue | Dogs may otherwise seem surprisingly normal | Do not wait for obvious illness to investigate |
| Staging workup | Assesses spread and overall status | Helps with prognosis and treatment choice | Ask what tests will change decisions |
| Chemotherapy | Often aims for remission, not cure | Many dogs tolerate it better than owners fear | Discuss quality-of-life goals early |
| Prednisone before diagnosis | Can change test results and future options | Sometimes used too soon | Ask before starting steroids when possible |
| Relapse planning | Remission is often time-limited | Owners do better when the next-step plan is discussed upfront | Clarify what recheck milestones mean |
Lymphoma appointment checklist
| Measure or photograph enlarged nodes so changes are easier to track | |
| Ask which staging tests truly affect treatment decisions | |
| Discuss quality-of-life goals and budget honestly | |
| Start leftover steroids before diagnosis without asking | |
| Assume chemotherapy in dogs mirrors the human experience exactly | |
| Delay workup because the dog still seems bright |
For many families, the most helpful conversation is not 'Can we cure this?' but 'What amount of good time can we realistically preserve, and how?'
Prednisone given too early can temporarily shrink nodes and complicate both diagnosis and later treatment choices.
Lymphoma is one of the most common cancers in dogs, accounting for 7-24% of all canine tumors and 83% of all blood cancers. The good news: it responds to chemotherapy better than almost any other canine cancer. With treatment, most dogs with the most common form achieve remission and enjoy a good quality of life for 1-2+ years.
What Is Canine Lymphoma?
Lymphoma (lymphosarcoma) is a cancer of lymphocytes -- white blood cells that are a key part of the immune system. Lymphocytes are found throughout the body: in lymph nodes, spleen, liver, bone marrow, gastrointestinal tract, and skin. This explains why lymphoma can manifest in many different ways.
There are over 30 described forms of canine lymphoma, classified by: anatomical location, cell type (B-cell vs. T-cell), and grade (low vs. high). The most common form is multicentric lymphoma (involving lymph nodes throughout the body), accounting for roughly 80% of cases.
Breeds at Higher Risk
Golden Retrievers, Boxers, Bullmastiffs, Basset Hounds, Saint Bernards, Scottish Terriers, Airedale Terriers, and Bulldogs have significantly higher lymphoma rates than average. Golden Retrievers in particular have a cancer death rate of approximately 60% -- with lymphoma being one of the top causes. Researchers have identified several chromosomal abnormalities in Golden Retrievers with lymphoma.
Most dogs develop lymphoma between ages 6-9, though it can occur at any age.
The Four Main Forms
Multicentric (80% of cases): Enlarged lymph nodes throughout the body -- most visibly the submandibular (under jaw), prescapular (shoulder), and inguinal (groin) nodes. Nodes feel rubbery and firm. Affected dogs may initially seem healthy despite dramatically enlarged nodes.
Alimentary/gastrointestinal (7%): Affects the GI tract; signs include vomiting, diarrhea, weight loss, and abdominal pain. Harder to treat; poorer prognosis than multicentric.
Mediastinal (5%): Affects lymph nodes in the chest. Signs: breathing difficulty, coughing, swelling of the head/forelegs (from vena cava compression), regurgitation. Associated with hypercalcemia (elevated blood calcium) in T-cell forms.
Cutaneous (5%): Affects the skin; appears as itchy raised plaques, ulcerated areas, or scaling. Highly variable prognosis depending on cell type.
Diagnosis and Staging
Diagnosis requires tissue sampling. Fine needle aspirate (FNA) of an enlarged lymph node is the first step -- a needle withdraws cells from the node for cytology. FNA is quick, minimally invasive, and gives a presumptive diagnosis in most cases. Excisional biopsy provides more information (grade, architecture) and is recommended when FNA is inconclusive.
Immunophenotyping (flow cytometry or immunohistochemistry) determines whether the cancer is B-cell or T-cell -- this is critical because B-cell lymphoma has dramatically better response rates to chemotherapy (approximately 80-90% remission) vs. T-cell (50-70% remission, shorter duration).
Staging (WHO system):
- Stage I: Single node involvement
- Stage II: Multiple nodes in one region
- Stage III: Generalized node involvement
- Stage IV: Liver/spleen involvement
- Stage V: Blood/bone marrow involvement
Staging workup: CBC, chemistry panel, urinalysis, thoracic X-rays, abdominal ultrasound, bone marrow aspirate (for Stage V assessment). Substage a (no clinical illness) has significantly better outcomes than substage b (clinically ill).
Treatment Options
CHOP chemotherapy protocol: The gold standard for multicentric B-cell lymphoma. CHOP uses cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone in a 25-week protocol. First remission rate: 80-90%; median survival 12-14 months; roughly 20-25% of dogs survive 2+ years.
COP protocol: Cyclophosphamide, vincristine, prednisone -- no doxorubicin. Lower cost, lower remission rate, shorter remission duration. An option when doxorubicin is cost-prohibitive.
Prednisone alone: Produces temporary remission in many dogs (1-3 months) but primes the cancer to resist future chemotherapy. Using prednisone before discussing chemotherapy with an oncologist should be avoided if chemotherapy is a future option.
Rabacfosadine (Tanovea): FDA-approved chemotherapy for relapsed/refractory canine lymphoma. An option after first-line protocol failure.
Dogs on chemotherapy generally tolerate treatment much better than humans. Side effects occur in approximately 25-30% of treatment cycles but are usually mild (1-3 days of lethargy, reduced appetite, GI upset). Severe side effects requiring hospitalization occur in less than 5% of cycles.
Second Remission
When lymphoma relapses after CHOP, second remission is possible but shorter and harder to achieve. Rescue protocols include MOPP, LOPP, lomustine (CCNU), and others. Median second remission is typically 2-4 months.
Monitoring at Home
Owners can learn to check lymph node size at home by palpating submandibular, prescapular, popliteal (behind knees), and inguinal nodes. Changes in node size between scheduled visits should prompt early contact with the oncologist. Other warning signs: reduced energy, decreased appetite, GI upset, labored breathing.
Sources: Vail DM et al., 'Canine Lymphoma and Lymphoid Leukemia,' Withrow and MacEwen's Small Animal Clinical Oncology (6th ed, 2020); ACVIM consensus guidelines on canine lymphoma; VCOG (Veterinary Cooperative Oncology Group) clinical trial data; Merck Veterinary Manual -- Canine Lymphoma.